Autonomic dysregulation and the metabolic syndrome: Pathologic partners in an emerging global pandemic;Desequilíbrio autonômico e síndrome metabólica: Parceiros patológicos em uma pandemia global emergente

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 4, 2006, Pages

  Lopes, Heno Ferreira ^a   Egan, Brent M ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; CYTOKINE; ENDORPHIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSANOID; INSULIN; LEPTIN; LIOTHYRONINE; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

AGING; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE CLASSIFICATION; DYSLIPIDEMIA; ECONOMIC ASPECT; HEALTH PROGRAM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; SLEEP APNEA SYNDROME; SPECTROSCOPY; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION; ADRENERGIC SYSTEM; ANIMAL; BLOOD; EPIDEMIC; FEMALE; HEALTH; MALE; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; WORLD HEALTH;

EID: 33751380779     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Alberti KGMM, Zimmet PZ: Diagnosis and classification of diabetes mellitus: Part 1-provisional report of a WHO consultation. Diabetes Med. 1998; 15: 539-53.
2. The European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002; 28: 364-76.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97.
4. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002; 156: 1070-7.
5. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288: 2790-6.
6. Wilson PWF, D'Agostino RB, Parise H, Meigs JB. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Diabetes. 2002; 51 (suppl 2): A242.
7. Obesity: Preventing and managing the global epidemic: Report of a WHO Consultation on Obesity, Geneva, 3 - 5 June 1997. World Health Organization, 1998.
8. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995; 75: 473-86.
9. Esposito K, Pontillo A, Di Pala C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA. 2003; 289: 1799-804.
10. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor-1 and insulin resistance. Diab Metab Res Rev. 2000; 16: 192-201.
11. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999; 85: 753-66.
12. Facchini FS, Hua NW, Reaven GM, Stoohs RA. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Rad Biol Med. 2000; 29: 1302-6.
13. Rowley K, O'Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Curr Diab Rep. 2003; 3: 80-6.
14. Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep. 2003; 5: 247-54.
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356-9.
16. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Hemsfield SB. The Metabolic Syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988 - 1994. Arch Intern Med. 2003; 163: 427-36.
17. Prebble WE: Obesity: Observations on one thousand cases. Boston Med Surg J. 1923; 88: 617-21.
18. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995; 75: 473-86.
19. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994; 74: 761-811.
20. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999 - 2000. JAMA. 2002; 288: 1723-7.
21. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289: 76-9.
22. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001; 161: 1581-6.
23. US Bureau of the Census and Money Magazine projections.
24. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA. 2001; 286: 2845-8.
25. Gidding SS, Falkner B. Are we losing the game? Cardiovascular health in minority children. Ethnic Dis. 2002; 12: 171-3.
26. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obesity Research. 1998; 6: 97-106.
27. Garfinkel L. Overweight and cancer. Ann Int Med. 1985; 103 (6[part 2]): 1034-6.
28. Quesenberry CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Int Med. 1998; 158: 466-72.
29. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest. 1997; 100: 1166-73.
30. Bunker CH, Ukoli FA, Matthews KA, Kriska AM, Huston SL, Kuller LH. Weight threshold and blood pressure in a lean black population. Hypertension. 1995; 26: 616-23.
31. Bnerji MA, Faridi, N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999; 84: 137-44.
32. Snitker S, Macdonald I, Ravussin E, Astrup A. The sympathetic nervous system and obesity: Role in aetiology and treatment. Obesity Rev. 2000; 1: 5-15.
33. Esler M, Magdalena R, Wiesner G, Kaye D, Hasting J, Lambert G. Sympathetic nervous system and insulin resistance: From obesity to diabetes. Am J Hypertens. 2001; 14: 304S-309S.
34. Grassi G, Seravalle G, Dell-Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000; 36: 538-42.
35. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased α-adrenergic vasoconstriction in human essential hypertension. J Clin Invest. 1987; 80: 812-17.
36. Quillot D, Fluckiger L, Zannad F, Drouin P, Ziegler O. Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin-resistance. Clin Autonomic Res. 2001; 11: 79-86.
37. Gao YY, Lovejoy, Spart An, Gray GA, Keys LK, Partington C. Autonomic activity assessed by heart rate spectral analysis varies with fat distribution in obese women. Obesity Res. 1996; 4: 55-63.
38. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988; 31: 415-20.
39. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993; 21: 618-23.
40. Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension. 1999; 33 [part 2]: 548-53.
41. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S: Role of sympathetic nervous system and neuropeptides in obesity hypertenson. Braz J Med Biol Res. 2000; 33: 605-18.
42. Wofford MR, Anderson DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive -effect of α- and β-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001; 14: 694-8.
43. Sower JR, Nyby M, Stern N, Beck F, Baron S, Catania R, et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension. 1982; 4: 686-91.
44. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V. The determinants of plasma-renin activity in essential hypertension. Ann Int Med. 1978; 88: 746-52.
45. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effects of salt restriction greater in subjects with risk factor clustering. Am J Hypertens. 1994; 7: 886-93.
46. Rothwell NJ. Central regulation of thermogenesis. Crit Rev Neurobiol. 1994; 8: 1-10.
47. Carroll JF, Hunag M, Hester RL, Cockrell K, Mizelle HL. Hemodynamic alterations in hypertensive obese rabbits. Hypertension. 1995; 26: 465-70.
48. Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG. State-of-the-art lecture: Obesity-induced hypertension: New concepts from the emerging biology of obesity. Hypertension. 1999; 33 [part 2]: 537-41.
49. Hwang I-S, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987; 10: 512-16.
50. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension. 1992; 19 [suppl 1]: I67-I77.
51. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Kath V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Méd. 1989; 321: 580-85.
52. Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G. Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension. 1991; 17 [suppl III]: III29-III35.
53. Guyton AC: Blood pressure control-special role of the kidneys and body fluids. Science. 1991; 252: 1813-16.
54. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000; 36: 538-42.
55. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, et al. Body weight reduction, sympathetic nerve activity, and arterial baroreflex in obese normotensive humans. Circulation. 1998; 97: 2037-42.
56. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest. 1990; 85: 1844-52.
57. Andersson B, Elam M, Wallin BG, Björntorp P, Andersson OK. Effect of energy-restricted diet on sympathetic muscle nerve activity in obese women. Hypertension. 1991; 18: 783-9.
58. Jones PP, Snitker S, Skinner JS, Ravussin E. Gender differences in muscle sympathetic nerve activity: Effect of body fat distribution. Am J Physiol. 1996; 270: E363-E366.
59. Stern M, Haffner S. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis. 1986; 6: 123-9.
60. Heitmann BL. Body fat distribution in the adult Danish population aged 35 - 65 years: An epidemiological study. Internat J Obes. 1991; 58: 535-45.
61. MacMahon SW, Blacket RB, Macdonald GJ, Hall W. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. J Hypertens. 1984; 2: 85-91.
62. Emdin M, Gastaldelli A, Muscelli E, Macerata A, Natali A, Camastra S, et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: Effects of weight loss. Circulation. 2001; 103: 513-19.
63. Hirsch J, Leibel RL, Mackintosh R, Aguirre A. Heart rate variability as a measure of autonomic function during weight change in humans. Am J Physiol. 1991; 261: R1418-R1423.
64. Hausberg M, Hoffman RP, Somers VK, Sinkey CA, Mark AL, Anderson EA. Contrasting autonomic and hemodynamic effects of insulin in health elderly versus young subjects. Hypertension. 1997; 29: 700-5.
65. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 1992; 19: 621-7.
66. Wollenweider P, Tappy L, Randin D, Schneiter P, Jéquier E, Nicod P, et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993; 92: 147-54.
67. Monroe MB, Van Pelt RE, Schiller BC, Seals DR, Jones PP. Relation of leptin and insulin to adiposity-associated elevations in sympathetic activity with age in humans. Internat J Obes. 2000; 24: 1183-7.
68. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989; 83: 1168-73.
69. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YDI. Measurement of plasma glucose, free fatty acids, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes. 1988; 37: 1020-4.
70. Ferrannini E, Barrett EJ, Bevilacqua S. Effects of fatty acids on glucose production and utilization in man. J Clin Invest. 1983; 72: 1737-47.
71. Cabezas MC, deBruin TWA, deValk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993; 92: 160-8.
72. Bülow J, Madsen J, Hojgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scan J Clin Lab Invest. 1990; 50: 291-6.
73. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol. 1997; 273: R324-R330.
74. Hildebrandt DA, Kirk D, Hall JE. Renal and cardiovascular responses to chronic increases in cerebrovascular free fatty acids. Fed Proc. 1999; 13: 780 (abstract and personal communication).
75. Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM. Hemodynamic effects of lipids in humans. Am J Physiol. 2001; R280: 1674-9.
76. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997; 100: 1230-9.
77. Haastrup T, Stepniakowski KT, Goodfriend TL, Egan BM. Lipids enhance α1-adrenergic receptor mediated pressor reactivity. Hypertension. 1998; 32: 693-8.
78. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci. 1998; 95: 15090-5.
79. Fagot-Campagna A, Balkau B, Simon D, Warnet J-M, Claude J-R, Ducimetière P, et al. High free fatty acid concentration: An independent risk factor for hypertension in the Paris Prospective Study. Internat J Epidemiol. 1998; 27: 808-13.
80. Gadegbeku CA, Dhandayuthapani A, Sadler JE, Egan BM. Raising lipids acutely reduces baroreflex sensitivity. Am J Hypertension. 2002; 15: 479-85.
81. Paolisso G, Manzella D, Rosaria MR, Ragno E, Barbieri M, Varricchio G, et al. Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr. 2000; 72: 723-30.
82. Jouven X, Charles M-A, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation. 2001; 104: 756-61.
83. Chan JC, Cheung JC, Stehouwer CD, Emeis JJ, Tong PC, Ko GT, et al. The central roles of obesity-associated dyslipidaemia, endothlelial activation and cytokines in the Metabolic Syndrome-an analysis by structural equation modeling. Internat J Obes. 2002; 26: 994-1008.
84. Maguri SR, Hauser R, Schwartz J, Williams PL, Smith TJ, Christiani DC. Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation. 2001; 104: 986-91.
85. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab. 2000; 85: 1151-8.
86. O'Dea K, Esler M, Leonard P, Stockigt JR, Nestel P. Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism. 1982; 31: 896-9.
87. Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Hormone Metab Res. 2000; 21: 485-99.
88. Brody MJ, Kadowitz PJ. Prostaglandins as modulators of autonomic nervous system. Fed Proc. 1974; 33: 48-60.
89. Stjärne L. Enhancement by indomethacin of cold-induced hypersecretion of noradrenaline in the rat in vivo by suppression of PGE mediated feedback control? Acta Physiol Scand. 1972; 86: 388-97.
90. Qadri F, Carretero OA, Scicli AG. Centrally produced nitric oxide in the control of baroreceptor reflex sensitivity and blood pressure in normotensive and hypertensive spontaneously hypertensive rats. Jap J Pharmacol. 1999; 81: 279-85.
91. Tanioka H, Nakamura K, Fujimura S, Yoshida M, Suzuki-Kusaba M, Hisa H, et al. Facilitatory role of NO in neural norepinephrine release in the rat kidney. Am J Physiol. 2002; 282: R1436-R1442.
92. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension. 2001; 37 [part 2]: 670-6.
93. Konishi S, Tsunoo A, Otsuka M. Enkephalins presynaptically inhibit cholinergic transmission in sympathetic ganglia. Nature. 1979; 282: 515-16.
94. Paquali R, Cantobelli S, Casimirri F, Boroluzzi L, Boschi S, Capelli M, et al. The role of opioid peptides in the development of hyperinsulinemia in obese women with abdominal fat distribution. Metabolism. 1992; 41: 763-7.
95. McCubbin JA, Survit RS, Williams RB, Nemeroff CB, McNeilly M. Altered pituitary hormone response to naloxone in hypertension development. Hypertension. 1989; 14: 636-44.
96. Ramirez-Gonzalez MD, Tchakarov L, Garcia RM, Kunos G. β-endorphin acting on the brainstem is involved in the antihypertensive action of clonidine and α-methyldopa in rats. Circ Res. 1983; 53: 150-7.
97. Bouloux P-M, Grossman A, Al-Damluji S, Bailey T, Besser M. Enhancement of the sympathoadrenal response to the cold-pressor test by naloxone in man. Clin Sci. 1985; 69: 365-8.
98. Rothman RB, Xu H, Char GU, Kim A, De Costa BR, Rice KC, et al. Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the κ2B (enkephalin-sensitive) binding site. Peptides. 1993; 14: 17-20.
99. Balasubramaniam A. Clinical potential of neuropeptide Y family of hormones. Am J Surg. 2002; 183: 430-4.
100. Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Current Hypertension Reports. 2001; 3: 209-15.
101. Roux F, D'Ambrosio C, Mohsenin V. Sleep-related breathing disorders and cardiovascular disease. Am J Med. 2000; 108: 396-402.
102. Fletcher EC, Lesske J, Behm R, Miller CC 3rd, Stauss H, Unger T. Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J Appl Physiol. 1992; 1978-84.
103. Ries DJ, Morrison S, Ruggiero DA. The C1 area of the brainstem in tonic and reflex control of blood pressure: State of the art lecture. Hypertension. 1988; 11 [Suppl 1]: I8-I13.
104. Johnson EH. Interrelationships between psychological factors, overweight, and blood pressure in adolescents. J Adolesc Health Care. 1990; 11: 310-18.